Clinical Trials for Cervical Cancer

201704051

CPTAC III: Clinical Proteomic Analysis Consortium – Phase III Tissue Source Site Phase N/A Principal Investigator Mutch, David Disease Site Corpus Uteri

202005122

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Phase I/II Principal Investigator Ward, Jeffrey Disease Site Breast; Cervix; Corpus Uteri; Ill-Defined Sites; Lip, Oral Cavity…

202101017

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigators Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer Phase III (Cancer Control) Principal Investigator Thaker, Premal Disease Site Cervix Learn more…

202101091

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations Phase II (Cancer Control) Principal Investigator Thaker, Premal Disease…